Immunotherapy through immune checkpoints blockade and its subsequent clinical
application has revolutionized the treatment of a spectrum of solid tumors. Blockade of …

Background Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are
frequently expressed in T-cell lymphomas. This provides a rationale for exploration of …

Abstract Purpose of Review Programmed cell death protein-1 (PD-1) is currently the most
extensively studied inhibitory checkpoint molecule. Many malignant neoplasms express the …

Background Recently, unprecedented clinical efficacy was observed during treatment of
many solid tumors because of the introduction of programmed cell death 1 (PD …

Cancers can evade the host immune system by inducing upregulation of immune inhibitory
signals. Anti-programmed cell death-1 (PD-1) monoclonal antibodies block these inhibitory …

Leukemia cells prevent immune system from clearing tumor cells by inducing the
immunosuppression of the bone marrow (BM) microenvironment. In recent years, further …

The immune checkpoint programmed death receptor 1 (PD‐1) and programmed death
ligand 1 (PD‐L1) are biologically important immunosuppressive molecules, and the PD …

The success of immunotherapy using immune checkpoint blockade in solid tumors and in
relapsed/refractory classical Hodgkin lymphoma and chronic lymphocytic leukemia holds …

Abstract Programmed death-1 (PD-1) is a co-inhibitory molecule and is seen in CD4+ and
CD8+ T cells. Upon binding to its ligands, programmed death ligand-1 (PD-L1) and-2 (PD …

Leukemia poses a significant clinical challenge due to its swift onset, rapid progression, and
treatment-related complications. Tumor immune evasion, facilitated by immune checkpoints …